MRNA cancer shot shows promise in early trial
Disease control
Not yet recruiting
This early-phase trial tests a new mRNA-based immunotherapy called PMC2129G12 in 60 adults with advanced solid tumors that have not responded to standard treatments. The therapy is injected directly into tumors to help the body's immune T cells attack cancer cells. The main goals…
Phase: PHASE1, PHASE2 • Sponsor: IntraAb, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC